Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. KNX
10. KMI

Go back to Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results

Entera Bio Ltd. (ENTX) Reports Q1 Loss of $0.16

May 21, 2020 6:33 AM EDT

Entera Bio Ltd. (NASDAQ: ENTX) reported Q1 EPS of ($0.16), versus ($0.26) reported last year.

First Quarter 2020 and Recent Highlights

Continued Development of EB612: Entera continues to make progress on the determination of a formulation of EB612 that could be used to support the initiation in 2021 of a Phase 2b or Phase 3 clinical trial in patients with hypoparathyroidism. Maintained Financial Flexibility to Support Operations and Business Development: After completion of a private placement of ordinary shares and warrants that raised gross proceeds of $14.3 million dollars following the final closing in February 2020 and... More